๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lymphoma
Clinical trial register · China

Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 15 Shanghai 9 Guangzhou 6 Fuzhou 4 Hangzhou 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Chinese PLA General Hospital3 Ruijin Hospital2 Liping Dou2 Liling Zhang1 RenJi Hospital1
Site location
Beijing15 Shanghai9 Guangzhou6 Fuzhou4 Hangzhou4
All 27 locations
Target enrolment
to

Lymphoma trials in China

40 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Phase โ…  Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
NCT07583771Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1
186
Shanghai
2026-06
Recruiting
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
NCT07779018Lymphoma
Liping Dou
Phase 2
30
Beijing
2026-04-01
Not yet open
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
NCT07483749Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
The Children's Hospital of Zhejiang University School of Medicine
Observational
400
Hangzhou, Ningbo
2026-03-25
Recruiting
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT07048353Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1
15
Wuhan
2026-03-01
Recruiting
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
NCT07587840Lymphoma
Liping Dou
Phase 2
20
Beijing
2026-01-01
Recruiting
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
NCT07138547Lymphoma
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2025-12-26
Not yet open
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
NCT07316907Hematologic Malignancies, Lymphoma
YANRU WANG
Phase 1
12
Zhenjiang
2025-12-22
Recruiting
AI-assisted Diagnosis of Malignant Brain Tumors
NCT07198256Gliomas, Brain Metastases, Adult, Lymphoma, Brain Tumor Adult
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2025-09-01
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
NCT07763054Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma
DrugLiposomal Amphotericin B
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Observational
30
Hainan
2025-08-01
Recruiting
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
NCT07305337Leukaemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Lymphoma
Zhongnan Hospital
Not applicable
196
Wuhan
2025-06-28
Recruiting
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
NCT06883526Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
60
Hangzhou
2025-05-16
Recruiting
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
NCT06895538Leukemia, MDS, Lymphoma
Peking University First Hospital
Phase 2/3
24
Beijing
2025-05-03
Recruiting
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
NCT06867536Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma
DrugsGlofitamab·Obinutuzumab
Liling Zhang
Phase 2
40
Wuhan
2025-04-01
Active, closed
Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma
NCT07094477Lymphoma
Daihong Liu
Phase 2
50
Beijing
2025-04-01
Recruiting
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
NCT06967038Primary Sjogren's Syndrome, Lymphoma
Bangdong Gong
Phase 1/2
6
Shanghai
2025-02-28
Recruiting
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
NCT06826118Lymphoma, Follicular Lymphoma, Refractory Lymphoma
DrugAxicabtagene Ciloleucel
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-02-08
Recruiting
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
NCT06971523Solid Tumor, Lymphoma
CytosinLab Therapeutics Co., Ltd.
Phase 1/2
224
Beijing
2024-12-25
Recruiting
CD70-targeted immunoPET Imaging of Malignant Cancers
NCT06852638Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
RenJi Hospital
Phase 2
300
Shanghai
2024-12-23
Recruiting
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
NCT07155954Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis
Peking University Third Hospital
Observational
779
Beijing
2024-10-23
Recruiting
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
NCT06592170Lymphoma
The First Hospital of Jilin University
Phase 1/2
35
Changchun
2024-08-13
Recruiting
Intratumoral CAN2109 in Subjects With Solid Tumors
NCT06332430Solid Tumor, Lymphoma
Canwell Biotech Limited
Phase 1
27
Guangzhou
2024-05-28
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Pembrolizumab
AstraZeneca
Phase 1/2
161
Beijing, Guangzhou, Shanghai
2024-01-23
Recruiting
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936Lymphoma
DrugsGlofitamab·Tocilizumab·Bendamustine·Obinutuzumab
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
Real-World Study of DLBCL With Different Genetic Subtypes
NCT06026488DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma
Ruijin Hospital
Observational
10,000
Shanghai
2023-10-01
Recruiting
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
NCT05948033Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2023-07-15
Recruiting
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
NCT05631886Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
DrugsAbraxane·Cyclophosphamide
Chinese PLA General Hospital
Phase 1
10
Beijing
2023-07-04
Recruiting
The Pathogenesis and Prognostic Factors of Lymphoma
NCT06203652Lymphoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-06-05
Active, closed
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
NCT05673785Lymphoma
DrugsBrentuximab Vedotin·Doxorubicin·Prednisone·Cyclophosphamide
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Not yet open
Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma
NCT05681403Lymphoma, Autologous Hematopoietic Stem Cell Transplantation
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
53
Xi'an
2023-01-15
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
50
Taiyuan
2022-09-07
Recruiting
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT05341557Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Betta Pharmaceuticals Co., Ltd.
Phase 1
110
Chaoyang, Cangzhou, Tianjin
2022-08-29
Recruiting
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma๏ผˆKeyplus-001๏ผ‰
NCT05357651Solid Tumor, Lymphoma
DrugLB1410
L & L Bio Co., Ltd., Ningbo, China
Phase 1
100
Shanghai
2022-08-12
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
DrugsEtoposide·Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Recruiting
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study
NCT04957901Lymphoma
Sun Yat-sen University
Observational
60
Guangzhou
2021-12-01
Recruiting
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
NCT04504526Lymphoma, Multiple Myeloma, Leukemia
Drug68Ga-pentixafor
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
50
Fuzhou
2020-08-07
Recruiting
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
NCT04263935Lymphoma, Gene Abnormality
Henan Cancer Hospital
Observational
200
Zhengzhou
2019-01-03
Recruiting
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
NCT03494296Lymphoma
First Affiliated Hospital of Harbin Medical University
Observational
150
Harbin
2018-03-01
Recruiting
China Lymphoma Patient Registry Study
NCT03313271Lymphoma
Jun Zhu
Observational
5,000
Beijing
2017-05-17
Recruiting
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
NCT06795113Lymphoma
Ruijin Hospital
Observational
4,000
Shanghai
2013-06-01
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies listing the condition Lymphoma.

How many Lymphoma trials are recruiting in China?

33 of the 40 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lymphoma), 40 studies
PhaseStudiesRecruitingShare
Observational111027.5%
Phase 29622.5%
Phase 1/27717.5%
Phase 16415%
Not applicable327.5%
Phase EARLY_PHASE1225%
Phase 2/3112.5%
Phase 3112.5%

Most active sponsors

Lead sponsors with the most studies (Lymphoma)
Lead sponsorStudiesRecruiting
Chinese PLA General Hospital33
Liping Dou22
Ruijin Hospital22
AstraZeneca11
Bangdong Gong11
BeiGene10
Betta Pharmaceuticals Co., Ltd.11
Canwell Biotech Limited11
Chipscreen Biosciences, Ltd.10
CytosinLab Therapeutics Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.